Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $42000.0.

  • Summit Therapeutics' Depreciation & Amortization (CF) rose 11000.0% to $42000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $126000.0, marking a year-over-year increase of 2989.69%. This contributed to the annual value of $89000.0 for FY2024, which is 5505.05% down from last year.
  • As of Q3 2025, Summit Therapeutics' Depreciation & Amortization (CF) stood at $42000.0, which was up 11000.0% from $37000.0 recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Depreciation & Amortization (CF) peaked at $99000.0 during Q2 2022, and registered a low of $20000.0 during Q2 2024.
  • In the last 5 years, Summit Therapeutics' Depreciation & Amortization (CF) had a median value of $46000.0 in 2023 and averaged $56315.8.
  • In the last 5 years, Summit Therapeutics' Depreciation & Amortization (CF) skyrocketed by 12571.43% in 2021 and then crashed by 7000.0% in 2024.
  • Summit Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $79000.0 in 2021, then increased by 11.39% to $88000.0 in 2022, then plummeted by 65.91% to $30000.0 in 2023, then decreased by 26.67% to $22000.0 in 2024, then soared by 90.91% to $42000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $42000.0 in Q3 2025, compared to $37000.0 in Q2 2025 and $25000.0 in Q1 2025.